Figure 2.

In Vivo Characterization and Comparison of MyC-CaP:hPSMA⁺ LDH-A KD and NC Tumors

(A and B) Low-power (A) and high-power (B) views of H&E-stained sections of representative MyC-CaP:hPSMA⁺ LDH-A KD and NC tumors. (C) CD31⁺ immunofluorescence (IF) staining. (D) Pimonidazole IF staining. (E) CD31⁺ IF staining density versus tumor volume (blue symbols indicate NC; red symbols indicate LDH-A KD; open symbols indicate no CAR T cells [NC, n = 6; LDH-A KD, n = 7]; filled symbols indicate with CAR T cells) [NC, n = 7; LDH-A KD, n = 8]). (F) Quantification of CD31⁺ vascular density (NC, n = 6; LDH-A KD, n = 7; p = 0.0061). (G) Quantification of ¹⁴C-IAP activity per mg of tumor weight (NC, n = 5; LDH-A KD, n = 5; p = 0.023). (H) Quantification of pimonidazole staining density (NC, n = 11; LDH-A KD, n = 8; p = 0.009) (Mean ± SEM).